SEARCH

SEARCH BY CITATION

References

  • Abdel-Daim, M., Funasaka, Y., Komoto, M., Nakagawa, Y., Yanagita, E., and Nishigori, C. (2010). Pharmacogenomics of metabotropic glutamate receptor subtype 1 and in vivo malignant melanoma formation. J. Dermatol. 37, 635646.
  • Abdel-Rahman, M.H., Yang, Y., Zhou, X.P., Craig, E.L., Davidorf, F.H., and Eng, C. (2006). High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J. Clin. Oncol. 24, 288295.
  • Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., and Beermann, F. (2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 40054011.
  • Aoki, H., and Moro, O. (2005). Upregulation of the IFN-gamma-stimulated genes in the development of delayed pigmented spots on the dorsal skin of F1 mice of HR-1 x HR/De. J. Invest. Dermatol. 124, 10531061.
  • Argenziano, G., Zalaudek, I., Ferrara, G., Hofmann-Wellenhof, R., and Soyer, H.P. (2007). Proposal of a new classification system for melanocytic naevi. Br. J. Dermatol. 157, 217227.
  • Balch, C.M., Soong, S.J., Gershenwald, J.E. et al. (2001). Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 36223634.
  • Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., Buzaid, A.C., Cochran, A.J., Coit, D.G., and Ding, S. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 61996206.
  • Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Ding, S., Byrd, D.R., Cascinelli, N., Cochran, A.J., Coit, D.G., and Eggermont, A.M. (2010). Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J. Clin. Oncol. 28, 24522459.
  • Bauer, J., Büttner, P., Murali, R., Okamoto, I., Kolaitis, N., Landi, M.T., Scolyer, R., and Bastian, B.C. (2011). BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 24, 345351.
  • Beadling, C., Jacobson-Dunlop, E., Hodi, F.S. et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 68216828.
  • Becker, J.C., Houben, R., Schrama, D., Voigt, H., Ugurel, S., and Reisfeld, R.A. (2010). Mouse models for melanoma: a personal perspective. Exp. Dermatol. 19, 157164.
  • Bevona, C., Goggins, W., Quinn, T., Fullerton, J., and Tsao, H. (2003). Cutaneous melanomas associated with nevi. Arch. Dermatol. 139, 16201624.
  • Box, N.F., and Terzian, T. (2008). The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 21, 525533.
  • Box, N.F., Torchia, E.C., and Roop, D.R. (2010). Are stem cell niches shared for skin cancers? Pigment Cell Melanoma Res. 23, 517520.
  • Bradl, M., Klein-Szanto, A., Porter, S., and Mintz, B. (1991). Malignant melanoma in transgenic mice. Proc. Natl Acad. Sci. USA 88, 164168.
  • Broekaert, S.M., Roym, R., Okamotom, I. et al. (2010). Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 23, 763770.
  • Broome Powell, M., Gause, P.R., Hyman, P., Gregus, J., Lluria-Prevatt, M., Nagle, R., and Bowden, G.T. (1999). Induction of melanoma in TPras transgenic mice. Carcinogenesis 20, 17471753.
  • Chan, J., Robinson, E.S., Atencio, J., Wang, Z., Kazianis, S., Coletta, L.D., Nairn, R.S., and McCarrey, J.R. (2001). Characterization of the CDKN2A and ARF genes in UV-induced melanocytic hyperplasias and melanomas of an opossum (Monodelphis domestica). Mol. Carcinog. 31, 1626.
  • Chana, J.S., Wilson, G.D., Cree, I.A., Alexander, R.A., Myatt, N., Neale, M., Foss, A.J., and Hungerford, J.L. (1999). c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br. J. Ophthalmol. 83, 110114.
  • Chin, L., Merlino, G., and DePinho, R. (1998). Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12, 34673481.
  • Chin, L., Tam, A., Pomerantz, J. et al. (1999). Essential role for oncogenic Ras in tumor maintenance. Nature 400, 468472.
  • Christophorou, M.A., Ringshausen, I., Finch, A.J., Swigart, L.B., and Evan, G.I. (2006). The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214217.
  • Clayton, E., Doupé, D.P., Klein, A.M., Winton, D.J., Simons, B.D., and Jones, P.H. (2007). A single type of progenitor cell maintains normal epidermis. Nature 446, 185189.
  • Croft, D.R., and Olson, M.F. (2008). Regulating the conversion between rounded and elongated modes of cancer cell movement. Cancer Cell 14, 349351.
  • Cruz III, F., Rubin, B.P., Wilson, D., Town, A., Schroeder, A., Haley, A., Bainbridge, T., Heinrich, M.C., and Corless, C.L. (2003). Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 63, 57615766.
  • Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 21352147.
  • Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 43404346.
  • Damsky Jr, W.E., and Bosenberg, M. (2010). Mouse melanoma models and cell lines. Pigment Cell Melanoma Res. 23, 853859.
  • Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky Jr, W.E., You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544552.
  • De Fabo, E.C., Noonan, F.P., Fears, T., and Merlino, G. (2004). Ultraviolet B but not ultraviolet A radiation initiates melanoma. Cancer Res. 64, 63726376.
  • Delmas, V., Beermann, F., Martinozzi, S. et al. (2007). Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 21, 29232935.
  • Dhomen, N., Reis-Filho, J.S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294303.
  • Fadloun, A., Kobi, D., Pointud, J.C. et al. (2007). The TFIID subunit TAF4 regulates keratinocyte proliferation and has cell-autonomous and non-cell-autonomous tumour suppressor activity in mouse epidermis. Development 134, 29472958.
  • Falchi, M., Bataille, V., Hayward, N.K. et al. (2009). Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41, 915919.
  • Fecher, L.A., Cummings, S.D., Keefe, M.J., and Alani, R.M. (2007). Toward a molecular classification of melanoma. J. Clin. Oncol. 25, 16061620.
  • von Felbert, V., Córdoba, F., Weissenberger, J., Vallan, C., Kato, M., Nakashima, I., Braathen, L.R., and Weis, J. (2005). Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am. J. Pathol. 66, 831841.
  • Ferguson, B., Konrad Muller, H., Handoko, H.Y., Khosrotehrani, K., Beermann, F., Hacker, E., Soyer, H.P., Bosenberg, M., and Walker, G.J. (2010). Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanomagenesis. Pigment Cell Melanoma Res. 23, 771780.
  • Florell, S.R., Thomas, J., and Grossman, D. (2007). Predominant formation of heavily pigmented dermal melanocytomas resembling ‘animal-type’ melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. J. Cutan. Pathol. 34, 667674.
  • Freedberg, D.E., Rigas, S.H., Russak, J. et al. (2008). Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl Cancer Inst. 100, 784795.
  • Gandini, S., Será, F., Cattaruzza, M.S., Pasquini, P., Picconi, O., Boyle, P., and Melchi, C.F. (2005). Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur. J. Cancer 41, 4560.
  • Garcia-Cruz, A., Flórez, A., de la Torre-Fraga, C., and Cruces Prado, M. (2009). Observational cross-sectional study comparing Breslow thickness of melanoma arising from naevi and melanoma de novo. Br. J. Dermatol. 161, 700702.
  • Garrido, M., and Bastian, B. (2010). KIT as a therapeutic target in melanoma. J. Invest. Dermatol. 130, 2027.
  • Gerstenblith, M.R., Shi, J., and Landi, M.T. (2010). Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res. 23, 587606.
  • Gleason, B.C., Crum, C.P., and Murphy, G.F. (2008). Expression patterns of MITF during human cutaneous embryogenesis: evidence for bulge epithelial expression and persistence of dermal melanoblasts. J. Cutan. Pathol. 35, 615622.
  • Goel, V.K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F.S., Hinds, P.W., and Haluska, F.G. (2009). Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28, 22892298.
  • Goodson, A.G., Cotter, M.A., Cassidy, P., Wade, M., Florell, S.R., Liu, T., Boucher, K.M., and Grossman, D. (2009). Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin. Cancer Res. 15, 74347440.
  • Green, A., Neale, R., Kelly, R., Smith, I., Ablett, E., Meyers, B., and Parsons, P. (1996). An animal model for human melanoma. Photochem. Photobiol. 64, 577580.
  • Green, A.C., Williams, G.M., Logan, V., and Strutton, G.M. (2011). Reduced melanoma after regular sunscreen use: randomized trial follow-up. J. Clin. Oncol. 29, 257263.
  • de Gruijl, F.R., Sterenborg, H.J., Forbes, P.D., Davies, R.E., Cole, C., Kelfkens, G., van Weelden, H., Slaper, H., and van der Leun, J.C. (1993). Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. Cancer Res. 53, 5360.
  • Ha, L., Ichikawa, T., Anver, M. et al. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl Acad. Sci. USA 104, 1096810973.
  • Hacker, E., Hayward, N.K., Dumenil, T., James, M.R., and Whiteman, D.C. (2010). The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J. Invest. Dermatol. 130, 241248.
  • Hasegawa, J., Goto, Y., Murata, H., Takata, M., Saida, T., and Imokawa, G. (2008). Downregulated melanogenic paracrine cytokine linkages in hypopigmented palmoplantar skin. Pigment Cell Melanoma Res. 21, 687699.
  • Herlyn, M., and Fukunaga-Kalabis, M. (2010). What is a good model for melanoma? J Invest Dermatol. 130, 911912.
  • Hirobe, T. (1984). Histochemical survey of the distribution of the epidermal melanoblasts and melanocytes in the mouse during fetal and postnatal periods. Anat. Rec. 208, 589594.
  • Hocker, T., and Tsao, H. (2007). Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 28, 578588.
  • Hocker, T.L., Singh, M.K., and Tsao, H. (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest. Dermatol. 128, 25752595.
  • Hofmann, U.B., Kauczok-Vetter, C.S., Houben, R., and Becker, J.C. (2009). Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin. Cancer Res. 15, 324329.
  • Huijbers, I.J., Krimpenfort, P., Chomez, P., van der Valk, M.A., Song, J.Y., Inderberg-Suso, E.M., Schmitt-Verhulst, A.M., Berns, A., and Van den Eynde, B.J. (2006). An inducible mouse model of melanoma expressing a defined tumor antigen. Cancer Res. 66, 32783286.
  • Hyter, S., Bajaj, G., Liang, X., Barbacid, M., Ganguli-Indra, G., and Indra, A.K. (2010). Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. Pigment Cell Melanoma Res. 23, 635648.
  • Jeong, J.H., Wang, Z., Guimaraes, A.S. et al. (2008). BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS ONE 3, e3949.
  • Johnson, M.W., Skuta, G.L., Kincaid, M.C., Nelson, C.C., and Wolter, J.R. (1989). Malignant melanoma of the iris in xeroderma pigmentosum. Arch. Ophthalmol. 107, 402407.
  • Kadariya, Y., Yin, B., Tang, B. et al. (2009). Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res. 15, 59615969.
  • Kannan, K., Sharpless, N.E., Xu, J., O’Hagan, R.C., Bosenberg, M., and Chin, L. (2003). Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc. Natl Acad. Sci. USA 100, 12211225.
  • Kato, M., Takahashi, M., Akhand, A.A., Liu, W., Dai, Y., Shimizu, S., Iwamoto, T., Suzuki, H., and Nakashima, I. (1998). Transgenic mouse model for skin malignant melanoma. Oncogene 17, 18851888.
  • Kim, M., Gans, J., Nogueira, C. et al. (2006). Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125, 12691281.
  • Kishore, K., Ghazvini, S., Char, D.H., Kroll, S., and Selle, J. (1996). p53 gene and cell cycling in uveal melanoma. Am. J. Ophthalmol. 121, 561567.
  • Kligman, L.H., and Sayre, R.M. (1991). An action spectrum for ultraviolet induced elastosis in hairless mice: quantification of elastosis by image analysis. Photochem. Photobiol. 53, 237242.
  • Klug, H., Tooze, J.A., Graff-Cherry, C., Anver, M., Noonan, F., Fears, T.R., Tucker, M., De Fabo, E., and Merlino, G. (2010). Sunscreen prevention of melanoma in man and mouse. Pigment Cell Melanoma Res. 23, 835837.
  • Kramer, T.R., Powell, M.B., Wilson, M.M., Salvatore, J., and Grossniklaus, H.E. (1998). Pigmented uveal tumours in a transgenic mouse model. Br. J. Ophthalmol. 82, 953960.
  • Kumasaka, M.Y., Yajima, I., Hossain, K., Iida, M., Tsuzuki, T., Ohno, T., Takahashi, M., Yanagisawa, M., and Kato, M. (2010). A novel mouse model for de novo melanoma. Cancer Res. 70, 2429.
  • Kunisada, T., Lu, S.Z., Yoshida, H. et al. (1998). Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J. Exp. Med. 187, 15651573.
  • Landsberg, J., Gaffal, E., Cron, M., Kohlmeyer, J., Renn, M., and Tüting, T. (2010). Autochthonous primary and metastatic melanomas in Hgf-Cdk4 R24C mice evade T-cell-mediated immune surveillance. Pigment Cell Melanoma Res. 23, 649660.
  • Larue, L., and Beermann, F. (2007). Cutaneous melanoma in genetically modified animals. Pigment Cell Res. 20, 485497.
  • Latendresse, J.R., Muskhelishvili, L., Warbritton, A., and Tolleson, W.H. (2007). Two cases of uveal amelanotic melanoma in transgenic Tyr-HRAS+ Ink4a/Arf heterozygous mice. Toxicol. Pathol. 35, 827832.
  • Lee, J.H., Choi, J.W., and Kim, Y.S. (2011). Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164, 776784.
  • Livet, J., Weissman, T.A., Kang, H., Draft, R.W., Lu, J., Bennis, R.A., Sanes, J.R., and Lichtman, J.W. (2007). Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450, 5662.
  • Lynch, H.T., Fusaro, R.M., Pester, J., and Lynch, J.F. (1980). Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma. Br. J. Cancer 42, 5870.
  • Maldonado, J.L., Fridlyand, J., Patel, H., Jain, A.N., Busam, K., Kageshita, T., Ono, T., Albertson, D.G., Pinkel, D., and Bastian, B.C. (2003). Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst. 95, 18781890.
  • McGee, H.M., Malley, R.C., Muller, H.K., and Woods, G.M. (2011). Neonatal exposure to UVR alters skin immune system development, and suppresses immunity in adulthood. Immunol. Cell Biol. 89, 767777.
  • McGowan, K.A., Li, J.Z., Park, C.Y. et al. (2008). Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat. Genet. 40, 963970.
  • McKenna, J.K., Florell, S.R., Goldman, G.D., and Bowen, G.M. (2006). Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol. Surg. 32, 493504.
  • Menzies, S.W., Greenoak, G.E., Abeywardana, C.M., Crotty, K.A., and O’Neill, M.E. (2004). UV light from 290 to 325 nm, but not broad-band UVA or visible light, augments the formation of melanocytic nevi in a guinea-pig model for human nevi. J. Invest. Dermatol. 123, 354360.
  • Metcalfe, D.D. (2008). Mast cells and mastocytosis. Blood 112, 946956.
  • Meyle, K.D., and Guldberg, P. (2009). Genetic risk factors for melanoma. Hum. Genet. 126, 499510.
  • Miller, A.J., and Mihm Jr, M.C. (2006). Melanoma. N. Engl. J. Med. 355, 5165.
  • Mintz, B., and Klein-Szanto, A.J. (1992). Malignancy of eye melanomas originating in the retinal pigment epithelium of transgenic mice after genetic ablation of choroidal melanocytes. Proc. Natl Acad. Sci. USA 89, 1142111425.
  • Misfeldt, M.L., and Grimm, D.R. (1994). Sinclair miniature swine: an animal model of human melanoma. Vet. Immunol. Immunopathol. 43, 167175.
  • Monahan, K., Rozenberg, G., Krishnamurthy, J., Johnson, S., Liu, W., Bradford, M., Horner, J., Depinho, R.A., and Sharpless, N.E. (2010). Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 29, 58095817.
  • Namkoong, J., Shin, S.S., Lee, H.J., Marín, Y.E., Wall, B.A., Goydos, J.S., and Chen, S. (2007). Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 67, 22982305.
  • Naus, N.C., Zuidervaart, W., Rayman, N., Slater, R., van Drunen, E., Ksander, B., Luyten, G.P., and Klein, A. (2000). Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int. J. Cancer 87, 151153.
  • Nogueira, C., Kim, K.H., Sung, H., Paraiso, K.H., Dannenberg, J.H., Bosenberg, M., Chin, L., and Kim, M. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 62226232.
  • Noonan, F.P., Recio, J.A., Takayama, H., Duray, P., Anver, M.R., Rush, W.L., De Fabo, E.C., and Merlino, G. (2001). Neonatal sunburn and melanoma in mice. Nature 413, 271272.
  • Otsuka, T., Takayama, H., Sharp, R. et al. (1998). c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 58, 51575167.
  • Pache, M., Glatz, K., Bösch, D. et al. (2003). Sequence analysis and high-throughput immunohistochemical profiling of kit (cd 117) expression in uveal melanoma using tissue microarrays. Virchows Arch. 443, 741744.
  • Patton, E.E., Mitchell, D.L., and Nairn, R.S. (2010). Genetic and environmental melanoma models in fish. Pigment Cell Melanoma Res. 23, 314337.
  • Pawlowski, A., and Lea, P.J. (1983). Nevi and melanoma induced by chemicals carcinogens in laboratory animals, similarities and differences with human lesions. J. Cutan. Pathol. 10, 81110.
  • Piliang, M.P. (2011). Acral lentiginous melanoma. Clin. Lab. Med. 31, 281288.
  • Pollock, P., Cohen-Solal, K., Sood, R. et al. (2003). Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34, 108112.
  • Rimoldi, D., Salvi, S., Liénard, D., Lejeune, F.J., Speiser, D., Zografos, L., and Cerottini, J.C. (2003). Lack of BRAF mutations in uveal melanoma. Cancer Res. 63, 57125715.
  • Romano, E., Schwartz, G.K., Chapman, P.B., Wolchock, J.D., and Carvajal, R.D. (2011). Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 12, 913922.
  • Rose, A.E., Poliseno, L., Wang, J., Clark, M., Pearlman, A., Wang, G., Vega, Y., Saenz de Miera, E.C., Medicherla, R. et al. (2011). Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res. 71, 25612571.
  • Rosengren Pielberg, G., Golovko, A., Sundström, E. et al. (2008). A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. Nat. Genet. 40, 10041009.
  • Saldanha, G., Purnell, D., Fletcher, A., Potter, L., Gillies, A., and Pringle, J.H. (2004). High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer 111, 705710.
  • Santoro, M., Carlomagno, F., Melillo, R.M., and Fusco, A. (2005). Dysfunction of the RET receptor in human cancer. Cell. Mol. Life Sci. 61, 29542964.
  • Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H., Marra, P., Pinner, S., Sahai, E., and Marshall, C.J. (2008). Rac activation and inactivation control plasticity of tumor cell movement. Cell 135, 510523.
  • Saxowskya, T., Meadowsa, K., Klunglandb, A., and Doetscha, W. (2008). 8-Oxoguanine-mediated transcriptional mutagenesis causes Ras activation in mammalian cells. Proc. Natl Acad. Sci. USA 105, 1887718882.
  • van Schanke, A., Jongsma, M.J., Bisschop, R., van Venrooij, G.M., Rebel, H., and de Gruijl, F.R. (2005). Single UVB overexposure stimulates melanocyte proliferation in murine skin, in contrast to fractionated or UVA-1 exposure. J. Invest. Dermatol. 124, 241247.
  • van Schanke, A., van Venrooij, G.M., Jongsma, M.J., Banus, H.A., Mullenders, L.H., van Kranen, H.J., and de Gruijl, F.R. (2006). Induction of nevi and skin tumors in Ink4a/Arf/Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures. Cancer Res. 66, 26082615.
  • Schmidt-Pokrzywniak, A., J¨ockel, K.-H., Bornfeld, N., Sauerwein, W., and Stang, A. (2009). Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Ophthalmology 116, 340348.
  • Shah, M., Bhoumik, A., Goel, V., Dewing, A., Breitwieser, W. et al. (2010). A role for ATF2 in regulating MITF and MELANOMA DEVELOPMENT. PLoS Genet. 6, e1001258.
  • Shapiro, R., Duquette, J., Roses, D., Nunes, I., Harris, M., Kamino, H., Wilson, L., and Rifkin, D. (1996). Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 56, 35973604.
  • Sharpless, N.E., Bardeesy, N., Lee, K.H., Carrasco, D., Castrillon, D.H., Aguirre, A.J., Wu, E.A., Horner, J.W., and DePinho, R.A. (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 8691.
  • Shields, J.A., and Shields, C.L. (2006). Prognostic factors for uveal melanoma. In Prognostic Factors in Cancer, M., Gospodarovicz, B., O’Sullivan, and L.H., Sobin, eds. 3rd edn. (Hoboken, NJ: Wiley-Liss), pp. 269272.
  • Shields, J.A., and Shields, S.C. (2007). Intraocular Tumors: An Atlas and Textbook, 2nd edn. (Philadelphia, PA, USA: Lippincott Williams & Wilkins).
  • Shin, S.S., Namkoong, J., Wall, B.A., Gleason, R., Lee, H.J., and Chen, S. (2008). Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res. 21, 368378.
  • Singh, A.D., De Potter, P., Fijal, B.A., Shields, C.L., Shields, J.A., and Elston, R.C. (1998). Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology 105, 195198.
  • Smith, S.H., Goldschmidt, M.H., and McManus, P.M. (2002). A comparative review of melanocytic neoplasms. Vet. Pathol. 39, 651678.
  • Smith, A.G. et al. (2008). Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. J. Biol. Chem. 283, 1256412570.
  • Smoller, B.R. (2006). Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod. Pathol. 19(Suppl. 2), S32S40.
  • Sotillo, R., García, J.F., Ortega, S., Martin, J., Dubus, P., Barbacid, M., and Malumbres, M. (2001). Invasive melanoma in Cdk4-targeted mice. Proc. Natl Acad. Sci. USA 98, 1331213317.
  • Syed, N.A., Windle, J.J., Darjatmoko, S.R. et al. (1998). Transgenic mice with pigmented intraocular tumors: tissue of origin and treatment. Invest. Ophthalmol. Vis. Sci. 39, 28002805.
  • Terzian, T., Suh, Y.A., Iwakuma, T., Post, S.M., Neumann, M., Lang, G.A., Van Pelt, C.S., and Lozano, G. (2008). The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 13371344.
  • Terzian, T., Torchia, E.C., Dai, D. et al. (2010). p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 23, 781794.
  • Terzian, T., Dumble, M., Arbab, F., Thaller, C., Donehower, L.A., Lozano, G., Justice, M.J., Roop, D.R., and Box, N.F. (2011). Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J. Pathol. 224, 540552.
  • Tolleson, W.H., Doss, J.C., Latendresse, J., Warbritton, A.R., Melchior, W.B. Jr, Chin, L., Dubielzig, R.R., and Albert, D.M. (2005). Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice. Arch Ophthalmol. 123, 10881094.
  • Tsao, H., Bevona, C., Goggins, W., and Quinn, T. (2003). The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch. Dermatol. 139, 282288.
  • Tucker, M.A., Fraser, M.C., Goldstein, A.M., Struewing, J.P., King, M.A., Crawford, J.T., Chiazze, E.A., Zametkin, D.P., Fontaine, L.S., and Clark Jr, W.H. (2002). A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 94, 31923209.
  • Umansky, V., Abschuetz, O., Osen, W., Ramacher, M., Zhao, F., Kato, M., and Schadendorf, D. (2008). Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res. 68, 94519458.
  • Van Raamsdonk, C.D., Fitch, K.R., Fuchs, H., de Angelis, M.H., and Barsh, G.S. (2004). Effects of G-protein mutations on skin color. Nat. Genet. 36, 961968.
  • Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599602.
  • Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B., Garrido, M.C., Vemula, S., Wiesner, T., Obenauf, A.C., Wackernagel, W., Green, G. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 21912199.
  • VanBrocklin, M.W., Robinson, J.P., Lastwika, K.J., Khoury, J.D., and Holmen, S.L. (2010). Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. Pigment Cell Melanoma Res. 23, 531541.
  • Vassilev, L.T., Vu, B.T., Graves, B. et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844848.
  • Vidwans, S.J., Flaherty, K.T., Fisher, D.E., Tenenbaum, J.M., Travers, M.D., and Shrager, J. (2011). A melanoma molecular disease model. PLoS ONE 6, e18257.
  • Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., and Bastian, B.C. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5, e120.
  • Walker, G. (2008). Cutaneous melanoma: how does ultraviolet light contribute to melanocyte transformation? Future Oncol. 4, 841856.
  • Walker, G.J., Kimlin, M.G., Hacker, E., Ravishankar, S., Muller, H.K., Beermann, F., and Hayward, N.K. (2009). Murine neonatal melanocytes exhibit a heightened proliferative response to ultraviolet radiation and migrate to the epidermal basal layer. J. Invest. Dermatol. 129, 184193.
  • Walker, G.J., Soyer, H.P., Handoko, H.Y., Ferguson, B., Kunisada, T., Khosrotehrani, K., Box, N.F., and Muller, H.K. (2011). Superficial spreading-like melanoma in Arf(−/−)::Tyr-Nras(Q61K)::K14-Kitl mice: keratinocyte Kit ligand expression sufficient to “translocate” melanomas from dermis to epidermis. J. Invest. Dermatol. 131, 13841387.
  • Wallander, M.L., Layfield, L.J., Emerson, L.L., Mamalis, N., Davis, D., Tripp, S.R., and Holden, J.A. (2011). IT mutations in ocular melanoma: frequency and anatomic distribution. Mod. Pathol. 2011, 10311035.
  • Wang, Z.Q., Si, L., Tang, Q., Lin, D., Fu, Z., Zhang, J., Cui, B., Zhu, Y., Kong, X., Deng, M., Xia, Y., Xu, H., Le, W., Hu, L., and Kong, X. (2009). Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet. 84, 672677.
  • Whiteman, D.C., Watt, P., Purdie, D.M., Hughes, M.C., Hayward, N.K., and Green, A.C. (2003). Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J. Natl Cancer Inst. 95, 806812.
  • Whiteman, D.C., Pavan, W.J., and Bastian, B.C. (2011). The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 24, 879897.
  • Willmore-Payne, C., Holden, J.A., Hirschowitz, S., and Layfield, L.J. (2006). BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum. Pathol. 37, 520527.
  • Wolnicka-Glubisz, A., Damsker, J., Constant, S., Corn, S., De Fabo, E., and Noonan, F. (2007). Deficient inflammatory response to UV radiation in neonatal mice. J. Leukoc. Biol. 81, 13521361.
  • Wu, J.M., Alvarez, H., García, P., Rojas, P.L., Wong, G., Maitra, A., Antonescu, C., and Montgomery, E.A. (2009). Melanoma hyperpigmentation is strongly associated with KIT alterations. Am. J. Dermatopathol. 31, 619625.
  • Yamaguchi, Y., Itami, S., Watabe, H., Yasumoto, K., Abdel-Malek, Z.A., Kubo, T., Rouzaud, F., Tanemura, A., Yoshikawa, K., and Hearing, V.J. (2004). Mesenchymal-epithelial interactions in the skin: increased expression of dickkopf1 by palmoplantar fibroblasts inhibits melanocyte growth and differentiation. J. Cell Biol. 165, 275285.
  • Yamazaki, F., Okamoto, H., Miyauchi-Hashimoto, H., Matsumura, Y., Itoh, T., Tanaka, K., Kunisada, T., and Horio, T. (2004). XPA gene-deficient, SCF-transgenic mice with epidermal melanin are resistant to UV-induced carcinogenesis. J. Invest. Dermatol. 123, 220228.
  • Yamazaki, F., Okamoto, H., Matsumura, Y., Tanaka, K., Kunisada, T., and Horio, T. (2005). Development of a new mouse model (xeroderma pigmentosum a-deficient, stem cell factor-transgenic) of ultraviolet B-induced melanoma. J Invest Dermatol. 125, 521525.
  • Yang, G., Curley, D., Bosenberg, M.W., and Tsao, H. (2007). Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. Cancer Res. 67, 56495657.
  • Yang, J., Splittgerber, R., Yull, F.E., Kantrow, S., Ayers, G.D., Karin, M., and Richmond, A. (2010). Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J. Clin. Invest. 120, 25632574.
  • Zaidi, M.R., Day, C.P., and Merlino, G. (2008). From UVs to metastases: modeling melanoma initiation and progression in the mouse. J. Invest. Dermatol. 128, 23812391.
  • Zaidi, M., De Fabo, E., Davis, S. et al. (2011). Ultraviolet B-induced activation of melanocytes is mediated through interferon-gamma secreted by macrophages. Nature 469, 548553.
  • Zalaudek, I., Marghoob, A.A., Scope, A., Leinweber, B., Ferrara, G., Hofmann-Wellenhof, R., Pellacani, G., Soyer, H.P., and Argenziano, G. (2008). Three roots of melanoma. Arch. Dermatol. 144, 13751379.
  • Zalaudek, I., Guelly, C., Pellacani, G. et al. (2011). The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J. Invest. Dermatol. 131, 542545.
  • Zappulla, J.P., Dubreuil, P., Desbois, S., Létard, S., Hamouda, N.B., Daëron, M., Delsol, G., Arock, M., and Liblau, R.S. (2005). Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J. Exp. Med. 202, 16351641.
  • Zhu, H., Reuhl, K., Zhang, X., Botha, R., Ryan, K., Wei, J., and Chen, S. (1998). Development of heritable melanoma in transgenic mice. J. Invest. Dermatol. 110, 247252.
  • Zuidervaart, W., van Nieuwpoort, F., Stark, M. et al. (2005). Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br. J. Cancer 92, 20322038.